Juzina (Sitagliptin Hydrochloride Monohydrate)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood sugar levels.

The specific dose of Juzina is determined by the prescribing healthcare professional based on the patient’s individual clinical profile, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy or lactation has not been fully established. The prescriber must weigh potential benefits against possible risks and decide whether the medication is appropriate for a pregnant or nursing patient.

To request Juzina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its glucose‑lowering effect is glucose‑dependent. Unlike insulin, it is taken orally and does not require injection, offering a convenient option for patients needing additional glycaemic control.

Juzina should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or extreme heat.

Juzina is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, though rare, include pancreatitis, severe allergic reactions such as anaphylaxis, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling of the face or throat, or unexplained skin blistering.

Juzina is contraindicated in patients with a known hypersensitivity to sitagliptin or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, a history of pancreatitis, or those taking medications that strongly inhibit CYP2C8 without dose adjustment.